Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SEL-212 in subjects with elevated blood uric acid
NCT02648269Phase 1Completed
- Sponsor
- Selecta Biosciences
- Start
- Dec 2015
- Primary completion
- Dec 2016
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of SEL-212 in gout (3 arms), sponsored by Selecta Biosciences. Primary endpoint: Safety and tolerability at 30 days. Started Dec 2015; status: completed.
02
Drugs
SEL-212
03
Conditions
gout
Beyond the preview
Go deeper on NCT02648269.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02648269.